Dupixent Approved in EU for Treating Children with CSU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy REGN?
Source: Newsfilter
- Pediatric Indication Expansion: Dupixent (dupilumab) has been approved in the EU as the first targeted therapy for chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking a significant breakthrough for the company in the pediatric market and expected to enhance market share.
- Clinical Study Support: The approval is based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's significant reduction in urticaria activity in adults, with efficacy data in children indicating its potential to improve symptoms, further solidifying Dupixent's market position.
- Improved Treatment Options: Dupixent offers a new treatment option for children whose symptoms are inadequately controlled by antihistamines, addressing the suffering many children face during critical growth years, which is expected to enhance their quality of life and reduce healthcare burdens.
- Global Market Outlook: With approvals in over 60 countries, the expansion of pediatric indications for Dupixent is anticipated to drive sales growth, further solidifying Sanofi and Regeneron's leadership in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 767.850
Low
637.00
Averages
808.50
High
1057
Current: 767.850
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dupixent Approved in EU for Children with CSU
- Expanded Indication for Children: Dupixent (dupilumab) has received EU approval for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of its indications and providing a new treatment option for this vulnerable population, which is expected to greatly improve their quality of life.
- Clinical Trial Validation: The approval is based on data from the LIBERTY-CUPID clinical trial program, demonstrating that Dupixent significantly reduced urticaria activity in adults, with safety and efficacy in children being consistent with adult profiles, further solidifying its position as a preferred treatment.
- Significant Market Potential: As one of the most widely used innovative antibody medicines globally, Dupixent's approval in the pediatric population is expected to drive sales growth, particularly in addressing chronic diseases driven by type 2 inflammation, meeting the urgent market demand for effective treatments.
- Raising Treatment Standards: The approval of Dupixent not only provides new treatment options for children but may also establish a new standard of care for CSU, reflecting the pharmaceutical industry's commitment to addressing unmet medical needs and enhancing market recognition of the drug.
See More
Dupixent Approved in EU for Treating Children with CSU
- Pediatric Indication Expansion: Dupixent (dupilumab) has been approved in the EU as the first targeted therapy for chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking a significant breakthrough for the company in the pediatric market and expected to enhance market share.
- Clinical Study Support: The approval is based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's significant reduction in urticaria activity in adults, with efficacy data in children indicating its potential to improve symptoms, further solidifying Dupixent's market position.
- Improved Treatment Options: Dupixent offers a new treatment option for children whose symptoms are inadequately controlled by antihistamines, addressing the suffering many children face during critical growth years, which is expected to enhance their quality of life and reduce healthcare burdens.
- Global Market Outlook: With approvals in over 60 countries, the expansion of pediatric indications for Dupixent is anticipated to drive sales growth, further solidifying Sanofi and Regeneron's leadership in the biopharmaceutical sector.
See More
Dupixent Approved in EU for Children with CSU
- Pediatric Indication Expansion: Dupixent has been approved in the EU for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11, based on data from the LIBERTY-CUPID clinical trial, which demonstrated significant efficacy in adults, indicating potential effectiveness in children.
- Diverse Indications: This approval expands Dupixent's indications in the EU to include four chronic diseases driven by type 2 inflammation, further solidifying its market position among pediatric populations and is expected to drive future sales growth.
- U.S. Application Progress: The supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in the U.S. for children aged 2 to 11 with CSU, showcasing the company's strategic intent for global expansion and potentially supporting future revenue growth.
- Optimistic Market Outlook: With approvals in multiple countries, Sanofi and Regeneron are poised to benefit from the expansion into the pediatric market, enhancing their competitiveness in chronic disease treatment and likely having a positive impact on financial performance.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Indication Expansion: Regeneron and Sanofi announced that Dupixent has been approved by the European Commission for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years, addressing a significant treatment gap for patients with inadequate response to antihistamines.
- Clinical Trial Support: The approval is based on data from the LIBERTY-CUPID clinical program, which includes efficacy results from two Phase 3 studies in adults and pharmacokinetic, safety, and efficacy data from the CUPIDKids Phase 3 trial in children, demonstrating Dupixent's broad applicability.
- Significant Efficacy: Results showed that Dupixent significantly reduced overall urticaria activity, including itch and hive severity, compared to placebo over 24 weeks, indicating its effectiveness in managing symptoms.
- Increased Patient Benefit: The proportion of patients achieving well-controlled disease and complete response was significantly higher in the Dupixent group compared to placebo, highlighting the potential clinical value of the drug in the pediatric population.
See More
Sanofi and Regeneron's Dupixent Receives EU Approval as the First Targeted Treatment for Young Children with Chronic Spontaneous Urticaria
Approval of Dupixent: The European Union has approved Dupixent (dupilumab) as the first targeted medicine for treating young children with chronic spontaneous urticaria.
Target Population: This approval specifically addresses the needs of young children suffering from this chronic skin condition, marking a significant advancement in pediatric care.
See More
Telix and Regeneron Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration on Radiopharmaceuticals: Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a partnership to jointly develop next-generation radiopharmaceutical therapies, leveraging Telix's development platform and Regeneron's expertise in biologics to target multiple solid tumor indications.
- Financial Support and Project Expansion: Under the agreement, Telix will receive an upfront payment of $40 million from Regeneron for access to its manufacturing platform, covering four initial therapeutic programs, with Regeneron having the option to expand the collaboration to include four additional programs, indicating strong mutual confidence in future growth.
- Shared Commercialization Costs: Both companies will equally share global commercialization costs and potential profits, while Telix retains the option to co-promote certain products, enhancing their competitive position in the precision oncology market.
- Milestone Payments and Royalties: Should Telix opt out of the co-funding model for a specific program, it could receive up to $535 million in development and commercial milestone payments, along with low double-digit royalties on future net sales, thereby increasing its financial flexibility.
See More
Dupixent Approved in EU for Children with CSU
- Expanded Indication for Children: Dupixent (dupilumab) has received EU approval for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11 years, marking a significant expansion of its indications and providing a new treatment option for this vulnerable population, which is expected to greatly improve their quality of life.
- Clinical Trial Validation: The approval is based on data from the LIBERTY-CUPID clinical trial program, demonstrating that Dupixent significantly reduced urticaria activity in adults, with safety and efficacy in children being consistent with adult profiles, further solidifying its position as a preferred treatment.
- Significant Market Potential: As one of the most widely used innovative antibody medicines globally, Dupixent's approval in the pediatric population is expected to drive sales growth, particularly in addressing chronic diseases driven by type 2 inflammation, meeting the urgent market demand for effective treatments.
- Raising Treatment Standards: The approval of Dupixent not only provides new treatment options for children but may also establish a new standard of care for CSU, reflecting the pharmaceutical industry's commitment to addressing unmet medical needs and enhancing market recognition of the drug.
See More
Dupixent Approved in EU for Treating Children with CSU
- Pediatric Indication Expansion: Dupixent (dupilumab) has been approved in the EU as the first targeted therapy for chronic spontaneous urticaria (CSU) in children aged 2 to 11, marking a significant breakthrough for the company in the pediatric market and expected to enhance market share.
- Clinical Study Support: The approval is based on data from the LIBERTY-CUPID clinical study program, demonstrating Dupixent's significant reduction in urticaria activity in adults, with efficacy data in children indicating its potential to improve symptoms, further solidifying Dupixent's market position.
- Improved Treatment Options: Dupixent offers a new treatment option for children whose symptoms are inadequately controlled by antihistamines, addressing the suffering many children face during critical growth years, which is expected to enhance their quality of life and reduce healthcare burdens.
- Global Market Outlook: With approvals in over 60 countries, the expansion of pediatric indications for Dupixent is anticipated to drive sales growth, further solidifying Sanofi and Regeneron's leadership in the biopharmaceutical sector.
See More
Dupixent Approved in EU for Children with CSU
- Pediatric Indication Expansion: Dupixent has been approved in the EU for treating moderate-to-severe chronic spontaneous urticaria (CSU) in children aged 2 to 11, based on data from the LIBERTY-CUPID clinical trial, which demonstrated significant efficacy in adults, indicating potential effectiveness in children.
- Diverse Indications: This approval expands Dupixent's indications in the EU to include four chronic diseases driven by type 2 inflammation, further solidifying its market position among pediatric populations and is expected to drive future sales growth.
- U.S. Application Progress: The supplemental Biologics License Application (sBLA) for Dupixent has been accepted for review in the U.S. for children aged 2 to 11 with CSU, showcasing the company's strategic intent for global expansion and potentially supporting future revenue growth.
- Optimistic Market Outlook: With approvals in multiple countries, Sanofi and Regeneron are poised to benefit from the expansion into the pediatric market, enhancing their competitiveness in chronic disease treatment and likely having a positive impact on financial performance.
See More
Dupixent Approved by EU for Pediatric CSU Treatment
- Indication Expansion: Regeneron and Sanofi announced that Dupixent has been approved by the European Commission for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years, addressing a significant treatment gap for patients with inadequate response to antihistamines.
- Clinical Trial Support: The approval is based on data from the LIBERTY-CUPID clinical program, which includes efficacy results from two Phase 3 studies in adults and pharmacokinetic, safety, and efficacy data from the CUPIDKids Phase 3 trial in children, demonstrating Dupixent's broad applicability.
- Significant Efficacy: Results showed that Dupixent significantly reduced overall urticaria activity, including itch and hive severity, compared to placebo over 24 weeks, indicating its effectiveness in managing symptoms.
- Increased Patient Benefit: The proportion of patients achieving well-controlled disease and complete response was significantly higher in the Dupixent group compared to placebo, highlighting the potential clinical value of the drug in the pediatric population.
See More
Sanofi and Regeneron's Dupixent Receives EU Approval as the First Targeted Treatment for Young Children with Chronic Spontaneous Urticaria
Approval of Dupixent: The European Union has approved Dupixent (dupilumab) as the first targeted medicine for treating young children with chronic spontaneous urticaria.
Target Population: This approval specifically addresses the needs of young children suffering from this chronic skin condition, marking a significant advancement in pediatric care.
See More
Telix and Regeneron Collaborate on Next-Gen Radiopharmaceuticals
- Collaboration on Radiopharmaceuticals: Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a partnership to jointly develop next-generation radiopharmaceutical therapies, leveraging Telix's development platform and Regeneron's expertise in biologics to target multiple solid tumor indications.
- Financial Support and Project Expansion: Under the agreement, Telix will receive an upfront payment of $40 million from Regeneron for access to its manufacturing platform, covering four initial therapeutic programs, with Regeneron having the option to expand the collaboration to include four additional programs, indicating strong mutual confidence in future growth.
- Shared Commercialization Costs: Both companies will equally share global commercialization costs and potential profits, while Telix retains the option to co-promote certain products, enhancing their competitive position in the precision oncology market.
- Milestone Payments and Royalties: Should Telix opt out of the co-funding model for a specific program, it could receive up to $535 million in development and commercial milestone payments, along with low double-digit royalties on future net sales, thereby increasing its financial flexibility.
See More
